Mira Pharmaceuticals Inc (MIRA)

NASD · Healthcare · Drug Manufacturers - General · USA

Mira Pharmaceuticals Inc is a micro cap company (market value under $300 million) in the Drug Manufacturers - General industry.

Mira Pharmaceuticals is a clinical-stage pharmaceutical company developing oral drug candidates targeting neurological, psychiatric, metabolic, and addiction-related conditions. The company holds exclusive rights to Ketamir-2, an NMDA receptor modulator undergoing early clinical testing for neuropathic pain; MIRA-55, a cannabinoid compound in preclinical work addressing inflammatory pain and brain disorders; and SKNY-1, a preclinical candidate for metabolic and behavioral indications.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Mira Pharmaceuticals Inc stock.

Our verdict on MIRA

Not valued: We cannot value this company yet.

ETFs with the most weight in MIRA

Browse

Peers in Drug Manufacturers - General

All 21 Drug Manufacturers - General stocks

Cheaper than MIRA in Drug Manufacturers - General

9 more in this industry show a wider margin of safety.

Is MIRA undervalued or overvalued?

We do not publish a verdict on MIRA yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.

What is the intrinsic value of MIRA?

We do not publish one (as of the 2026-11-17 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.